. Lastly, defects in peptide processing and transport have also been described in malignant cells (8) . Identification ofthe molecular mechanisms underlying structural and functional abnormalities in HLA class I antigens expressed by melanoma cells will suggest approaches to correct these defects. These approaches will have to be combined with vaccines to avoid having the potential benefits of immunotherapy for melanoma undermined by the resistance to T cell-mediated cytotoxicity that melanoma cells acquire because of abnormalities in HLA class I antigen expression.
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